Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial.
Kausik K RayLawrence Alan LeiterDirk Müller-WielandBertrand CariouHelen M ColhounRobert R HenryFrancisco J TinahonesMaja Bujas-BobanovicCatherine DomengerAlexia LetierceRita SamuelStephano Del PratoPublished in: Diabetes, obesity & metabolism (2018)
In individuals with T2DM and mixed dyslipidaemia on maximally tolerated statin, alirocumab showed superiority to UC in non-HDL cholesterol reduction and was generally well tolerated.